Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
Makaleler > Tam Makale · 2021
Yazarlar: MİNE DURUSU TANRIÖVER, Hamdi Levent Doganay, MURAT AKOVA, Hatice Rahmet Guner, Alpay Azap, SILA AKHAN, Sukran Kose, Fatma Sebnem Erdinc, EMİN HALİS AKALIN, Ömer Fehmi TABAK, Hüsnü PULLUKÇU, Ozgur Batum, Serap Simsek Yavuz, ÖZGE TURHAN, Mustafa Taner Yildirmak, IFTAHAR KÖKSAL, YEŞİM TAŞOVA, VOLKAN KORTEN, GÜRDAL YILMAZ, MUSTAFA KEMAL ÇELEN, Sedat Altin, Ilhami Celik, YAŞAR BAYINDIR, Ilkay Karaoglan, Aydin Yilmaz, AYKUT ÖZKUL, Hazal Gur, SERHAT ÜNAL
The Lancet, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2021, cilt 398, ss 213-222
DOI: 10.1016/s0140-6736(21)01429-x
Özet
Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.